Project Details
Description
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive UrothelialCarcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligiblefor or
| Status | Active |
|---|---|
| Effective start/end date | 9/6/23 → 9/30/33 |
Funding
- JANSSEN RESEARCH & DEVELOPMENT, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.